厄洛替尼治疗非小细胞肺癌后发生急性心肌梗死：一例报告。
Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.
作者信息
Ding Shanshan, Long Fei, Jiang Shujuan
机构信息
Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
出版信息
Oncol Lett. 2016 Jun;11(6):4240-4244. doi: 10.3892/ol.2016.4508. Epub 2016 Apr 28.
Abstract
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.
摘要
厄洛替尼是一种表皮生长因子受体酪氨酸激酶抑制剂，是一种用于治疗非小细胞肺癌（NSCLC）的口服靶向抗癌药物。先前的研究证实，厄洛替尼是安全的，患者耐受性良好。厄洛替尼治疗后观察到的最常见不良反应包括皮疹和轻度腹泻。在本研究中，报告了一名63岁男性非小细胞肺癌患者在接受厄洛替尼治疗一个月后发生急性心肌梗死的首例病例。本研究强调了临床医生在给予厄洛替尼后保持谨慎的重要性。在老年非小细胞肺癌患者和有冠心病病史的患者中，厄洛替尼治疗后必须仔细监测心功能，以便早期发现并快速治疗心肌梗死等严重不良反应。
相似文献
1
Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.厄洛替尼治疗非小细胞肺癌后发生急性心肌梗死：一例报告。
Oncol Lett. 2016 Jun;11(6):4240-4244. doi: 10.3892/ol.2016.4508. Epub 2016 Apr 28.
2
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼（OSI-774）用于非小细胞肺癌的II期临床试验数据。
Clin Lung Cancer. 2004 Dec;6 Suppl 1:S20-3. doi: 10.3816/clc.2004.s.010.
3
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.厄洛替尼：用于治疗非小细胞肺癌的小分子靶向疗法。
Clin Ther. 2005 Oct;27(10):1513-34. doi: 10.1016/j.clinthera.2005.10.014.
4
[Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases.].厄洛替尼治疗晚期非小细胞肺癌的临床观察：92例报告
Zhongguo Fei Ai Za Zhi. 2009 Dec 20;12(12):1305-8. doi: 10.3779/j.issn.1009-3419.2009.12.17.
5
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).一名先前耐受吉非替尼（易瑞沙）的患者在使用厄洛替尼（特罗凯）后出现间质性肺病。
J Oncol Pharm Pract. 2005 Sep;11(3):127-30. doi: 10.1191/1078155205jp158cr.
6
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.厄洛替尼治疗的非小细胞肺癌患者不良事件的建模与仿真框架
AAPS J. 2015 Nov;17(6):1483-91. doi: 10.1208/s12248-015-9815-8. Epub 2015 Aug 19.
7
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
8
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.厄洛替尼作为晚期非小细胞肺癌的维持治疗：一项多中心、随机、安慰剂对照的 3 期研究。
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
9
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].厄洛替尼治疗晚期非小细胞肺癌
Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):143-7.
10
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.厄洛替尼治疗在常规临床实践中铂类化疗后老年非小细胞肺癌患者-来自 ElderTac 研究的结果。
BMC Cancer. 2018 Mar 27;18(1):333. doi: 10.1186/s12885-018-4208-x.
引用本文的文献
1
Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的心脏毒性研究进展
Curr Treat Options Oncol. 2023 Dec;24(12):1935-1947. doi: 10.1007/s11864-023-01150-8. Epub 2023 Dec 28.
2
MicroRNAs expression profile in chemotherapy-induced cardiotoxicity in NSCLC using a co-culture model.使用共培养模型研究 NSCLC 化疗诱导性心脏毒性中的 microRNAs 表达谱。
Biomol Biomed. 2024 Jan 3;24(1):125-137. doi: 10.17305/bb.2023.9272.
3
Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan.台湾地区非小细胞肺癌患者酪氨酸激酶抑制剂的评估与生存及心血管结局。
JAMA Netw Open. 2023 May 1;6(5):e2313824. doi: 10.1001/jamanetworkopen.2023.13824.
4
Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data.用于癌症治疗相关心脏毒性早期检测和监测的多模态先进心血管与分子成像以及人工智能和大数据的作用
Front Cardiovasc Med. 2022 Mar 15;9:829553. doi: 10.3389/fcvm.2022.829553. eCollection 2022.
5
Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas.微创和浸润前肺腺癌的动态图像进展评估
Ann Transl Med. 2021 May;9(9):804. doi: 10.21037/atm-21-1994.
6
In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.基于组合分类器的药物致心血管并发症的计算药剂流行病学评估
J Chem Inf Model. 2018 May 29;58(5):943-956. doi: 10.1021/acs.jcim.7b00641. Epub 2018 May 10.
本文引用的文献
1
An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer.美国胸科学会/欧洲呼吸学会官方声明：肺科医生在肺癌诊断和管理中的作用。
Am J Respir Crit Care Med. 2013 Aug 15;188(4):503-7. doi: 10.1164/rccm.201307-1269ST.
2
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.克唑替尼、舒尼替尼、厄洛替尼和尼罗替尼在人心肌细胞中的多参数体外毒性测试。
Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55. doi: 10.1016/j.taap.2013.04.027. Epub 2013 May 21.
3
[Chinese guidelines on the diagnosis and treatment of primary lung cancer
(2011 version)].《原发性肺癌诊疗规范（2011年版）》
Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):677-88. doi: 10.3779/j.issn.1009-3419.2012.12.01.
4
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].[厄洛替尼诱发间质性肺疾病4例并文献复习]
Zhongguo Fei Ai Za Zhi. 2012 Aug;15(8):494-8. doi: 10.3779/j.issn.1009-3419.2012.08.08.
5
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.一线厄洛替尼治疗老年晚期非小细胞肺癌患者的疗效和安全性。
Oncol Rep. 2012 Aug;28(2):721-7. doi: 10.3892/or.2012.1824. Epub 2012 May 18.
6
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.维持厄洛替尼治疗晚期非小细胞肺癌亚洲患者的疗效和安全性：III 期随机 SATURN 研究的亚组分析。
Lung Cancer. 2012 Aug;77(2):339-45. doi: 10.1016/j.lungcan.2012.03.012. Epub 2012 Apr 10.
7
Reviewing the safety of erlotinib in non-small cell lung cancer.审查厄洛替尼在非小细胞肺癌中的安全性。
Expert Opin Drug Saf. 2011 Jan;10(1):147-57. doi: 10.1517/14740338.2011.540799. Epub 2010 Dec 8.
8
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.厄洛替尼治疗晚期非小细胞肺癌的疗效和安全性：全球 IV 期 Tarceva 肺癌生存治疗研究的结果。
J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0.
9
Cardiotoxicity induced by tyrosine kinase inhibitors.酪氨酸激酶抑制剂所致心脏毒性。
Acta Oncol. 2009;48(7):964-70. doi: 10.1080/02841860903229124.
10
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.与酪氨酸激酶抑制剂舒尼替尼相关的心脏毒性。
Lancet. 2007 Dec 15;370(9604):2011-9. doi: 10.1016/S0140-6736(07)61865-0.
Zotero 插件